Corient Private Wealth LP Boosts Position in Pfizer Inc. $PFE

Corient Private Wealth LP boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.7% in the second quarter, HoldingsChannel reports. The institutional investor owned 2,959,995 shares of the biopharmaceutical company’s stock after purchasing an additional 401,566 shares during the period. Corient Private Wealth LP’s holdings in Pfizer were worth $67,839,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Norges Bank purchased a new position in shares of Pfizer during the fourth quarter worth approximately $1,830,986,000. Bank of America Corp DE purchased a new stake in shares of Pfizer in the second quarter valued at approximately $1,049,602,000. BlackRock Inc. grew its stake in Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares in the last quarter. Morgan Stanley grew its stake in Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Pfizer by 38.9% during the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Bank of America decreased their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Wolfe Research reissued an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. BMO Capital Markets decreased their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. UBS Group reaffirmed a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Trading Down 0.8%

Shares of NYSE PFE opened at $28.33 on Thursday. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The business has a fifty day moving average price of $25.44 and a 200 day moving average price of $26.29. The stock has a market capitalization of $161.47 billion, a P/E ratio of 37.28 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer’s payout ratio is presently 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer has started a European Medicines Agency review for its Lyme disease vaccine. The review is an important regulatory step that could expand Pfizer’s longer-term vaccine portfolio, although it does not guarantee approval or near-term revenue. Pfizer Starts EMA Review For Its Lyme Disease Vaccine
• Positive Sentiment: Recent comparisons with Bristol Myers Squibb suggest Pfizer’s valuation, diversification and oncology portfolio may offer an attractive risk-reward profile. This supports the view that the stock could benefit if new medicines successfully offset declining legacy-product sales. PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
• Positive Sentiment: Analysts are focused on Pfizer’s post-second-quarter pipeline and whether upcoming medicines can reset the company’s growth trajectory. The opportunity is meaningful because Pfizer recently exceeded quarterly earnings and revenue expectations, but execution remains key. How Is Pfizer Shaping Its S&P 500 Pipeline After Q2?
• Neutral Sentiment: Pfizer’s dividend remains appealing to income-oriented investors, but comparisons with Abbott Laboratories emphasize that Pfizer offers more turnaround potential while Abbott has a steadier dividend-growth record and broader diversification. Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
• Neutral Sentiment: Brokerages collectively rate Pfizer “Hold,” indicating that analysts see potential value but lack a strong consensus catalyst for a decisive re-rating. Pfizer Receives Consensus Recommendation of Hold
• Negative Sentiment: Investor caution persists over Pfizer’s need to restore growth before major patent expirations arrive. Articles discussing new medicines frame the pipeline as necessary to counterbalance expected pressure on established products, limiting enthusiasm until launches and approvals produce measurable results. Can New Medicines Reset the Growth Story?

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.